Haleon (NYSE:HLN) Downgraded by Morgan Stanley to “Equal Weight”

Morgan Stanley lowered shares of Haleon (NYSE:HLN) from an overweight rating to an equal weight rating in a report released on Friday morning, MarketBeat reports.

Other equities research analysts have also issued research reports about the company. UBS Group raised Haleon to a “strong-buy” rating in a research note on Tuesday, October 1st. Sanford C. Bernstein downgraded Haleon from an “outperform” rating to a “market perform” rating in a research report on Wednesday. Three equities research analysts have rated the stock with a hold rating, three have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $10.95.

Haleon Stock Performance

NYSE:HLN opened at $9.11 on Friday. Haleon has a twelve month low of $7.89 and a twelve month high of $10.80. The company has a market capitalization of $41.24 billion, a P/E ratio of 26.79, a price-to-earnings-growth ratio of 2.95 and a beta of 0.29. The company has a current ratio of 0.84, a quick ratio of 0.58 and a debt-to-equity ratio of 0.44. The firm has a 50-day moving average price of $9.61 and a two-hundred day moving average price of $9.67.

Institutional Trading of Haleon

Hedge funds and other institutional investors have recently bought and sold shares of the company. Baker Tilly Wealth Management LLC boosted its holdings in shares of Haleon by 13.6% during the fourth quarter. Baker Tilly Wealth Management LLC now owns 67,384 shares of the company’s stock worth $643,000 after purchasing an additional 8,079 shares during the last quarter. Douglas Lane & Associates LLC lifted its position in Haleon by 1.9% during the fourth quarter. Douglas Lane & Associates LLC now owns 8,624,149 shares of the company’s stock worth $82,274,000 after buying an additional 161,865 shares during the period. GAMMA Investing LLC boosted its stake in Haleon by 41.3% in the 4th quarter. GAMMA Investing LLC now owns 21,258 shares of the company’s stock worth $203,000 after buying an additional 6,215 shares during the last quarter. Versant Capital Management Inc grew its holdings in Haleon by 2,029.1% in the 4th quarter. Versant Capital Management Inc now owns 3,513 shares of the company’s stock valued at $34,000 after buying an additional 3,348 shares during the period. Finally, JPMorgan Chase & Co. grew its holdings in Haleon by 25.3% in the 3rd quarter. JPMorgan Chase & Co. now owns 5,084,202 shares of the company’s stock valued at $53,791,000 after buying an additional 1,026,939 shares during the period. 6.67% of the stock is owned by hedge funds and other institutional investors.

Haleon Company Profile

Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands.